LAVA Therapeutics NV (LAVA Therapeutics NV) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV Change In Inventory?

LAVA Therapeutics NV's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means LAVA Therapeutics NV's inventory stayed the same from Dec. 2023 to Mar. 2024 .

LAVA Therapeutics NV's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means LAVA Therapeutics NV's inventory stayed the same from Dec. 2022 to Dec. 2023 .

LAVA Therapeutics NV's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. LAVA Therapeutics NV's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.00.

LAVA Therapeutics NV Change In Inventory Historical Data

The historical data trend for LAVA Therapeutics NV's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV Change In Inventory Chart

LAVA Therapeutics NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

LAVA Therapeutics NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial													-	-	-	-	-

LAVA Therapeutics NV Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

LAVA Therapeutics NV (NAS:LVTX) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

LAVA Therapeutics NV's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

LAVA Therapeutics NV's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

LAVA Therapeutics NV's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	6.992
	=	0.00

LAVA Therapeutics NV Change In Inventory Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

4PKB:Germany

Address

Yalelaan 62, Utrecht, UT, NLD, 3584 CM

Website

https://www.lavatherapeutics.com

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.